Should You Buy Arena Pharmaceuticals, Inc. (ARNA) Stock After it Is Lower By 0.58% in a Week?

Friday, January 14, 2022 02:54 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Arena Pharmaceuticals, Inc. (ARNA) Stock After it Is Lower By 0.58% in a Week?

Arena Pharmaceuticals, Inc. (ARNA) stock has fallen 0.58% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Arena Pharmaceuticals, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ARNA!

See Full ARNA Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With ARNA Stock Today?

Arena Pharmaceuticals, Inc. (ARNA) stock has gained 0.18% while the S&P 500 has fallen -0.36% as of 2:53 PM on Friday, Jan 14. ARNA is higher by $0.17 from the previous closing price of $92.47 on volume of 973,068 shares. Over the past year the S&P 500 has risen 21.85% while ARNA is higher by 18.30%. ARNA lost -$9.69 per share in the over the last 12 months.

More About Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain. Click Here to get the full Stock Report for Arena Pharmaceuticals, Inc. stock.